Abstract | OBJECTIVE: METHODS: RESULTS AND CONCLUSION: Median age was 60 years. Median follow-up time was 11.4 months. Overall survival did not reach the median, and 1-year overall survival was 67%. The response rate was 50% (64% at first line), and progression-free survival was 4.8 months (7.3 months at first line). Grade 3-4 hematologic adverse events were seen in 29 patients (66%) and Grade 3-4 non-hematologic adverse events were seen in 20 patients (45%), but no patients died of adverse events. Multivariate analysis showed a statistically significant relationship with neuron-specific enolase elevation and poor overall survival (P= 0.016, hazard ratio 6.261, 95% confidence interval). The combination chemotherapy of irinotecan and cisplatin is moderately effective and feasible, and it should be considered as a treatment option for poorly differentiated neuroendocrine carcinoma.
|
Authors | Kenji Nakano, Shunji Takahashi, Takeshi Yuasa, Noriko Nishimura, Yuko Mishima, Sakura Sakajiri, Masahiro Yokoyama, Naoko Tsuyama, Yuichi Ishikawa, Kiyohiko Hatake |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 42
Issue 8
Pg. 697-703
(Aug 2012)
ISSN: 1465-3621 [Electronic] England |
PMID | 22701038
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Irinotecan
- Cisplatin
- Camptothecin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Carcinoma, Neuroendocrine
(drug therapy, pathology)
- Cell Differentiation
- Cisplatin
(administration & dosage)
- Disease-Free Survival
- Drug Administration Schedule
- Feasibility Studies
- Female
- Humans
- Irinotecan
- Male
- Middle Aged
- Prognosis
- Retrospective Studies
|